Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439910 | 0.91 | BRD4 (0.49) | TP53KDM4ENPSR1BRD4HTT | |
| SCHEMBL3439912 | 0.89 | MEN1 (0.45) | TP53KDM4ENPSR1BRD4HTT | |
| SCHEMBL10018495 | 0.87 | TP53 (0.61) | TP53KDM4ENPSR1HTTLMNA | |
| SCHEMBL3439914 | 0.80 | ATM (0.47) | TP53KDM4ENPSR1BRD4HTT | |
| SCHEMBL2618367 | 0.79 | KDM4E (0.44) | TP53KDM4ENPSR1BRD4HTT | |
| SCHEMBL2607666 | 0.78 | CYP1A2 (0.48) | LMNAKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL2618364 | 0.78 | ALDH1A1 (0.50) | BRD4KMT2AALDH1A1MEN1CYP2C19 | |
| SCHEMBL3439908 | 0.77 | ALDH1A1 (0.49) | KDM4ELMNAALDH1A1GAAMAPT | |
| SCHEMBL2602437 | 0.74 | ALDH1A1 (0.43) | TP53KDM4ENPSR1HTTLMNA | |
| SCHEMBL3439933 | 0.70 | TP53 (0.50) | TP53KDM4EBRD4HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329728-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-c]pyridine compounds | SPELMAN COLLEGE (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120095038-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095038-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | MKI67, CCNI, TYMP | TP53 89/4885KDM4E 1051/4885NPSR1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.